An organ transplant drug from Bristol-Myers Squibb Co called as belatacept has received backing from an expert panel of the Food and Drug Administration. The panel voted 13-5 in favor of the drug, which is given to organ transplant recipients to prevent rejection.
Bristol's drugs is thought to be better than older drugs, which caused headaches, nausea and liver toxicity. In a study, patients on belatacept had improved kidney function and lower blood pressure, which are key indicators of survival.
AdvertisementThe FDA is not required to follow the panel's recommendations, but it usually does so.